-+ 0.00%
-+ 0.00%
-+ 0.00%

ZENAS BIOPHARMA ANNOUNCES PRICING OF CONCURRENT PUBLIC OFFERINGS OF 2.50% CONVERTIBLE SENIOR NOTES DUE 2032 AND COMMON STOCK WITH AGGREGATE GROSS PROCEEDS OF $300.0 MILLION

Reuters·03/27/2026 04:12:31

Please log in to view news